Publications by authors named "Fail Ageev"

Claim this Profile
T
The Prognostic Role of the Left Atrium in Hypertensive Patients with HFpEF: Does Function Matter More than Structure?
Artem Ovchinnikov, Alexandra Potekhina, Anastasiia Filatova, Olga Svirida, Maria Sobolevskaya, Fail Ageev

Life (Basel)· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of empagliflozin on functional capacity, LV filling pressure, and cardiac reserves in patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction: a randomized controlled open-label trial.
Artem Ovchinnikov, Alexandra Potekhina, Anastasiia Filatova, Olga Svirida, Kristina Zherebchikova, Fail Ageev

Cardiovasc Diabetol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Statins in Heart Failure with Preserved Ejection Fraction: Current Evidence and Perspectives.
Artem Ovchinnikov, Alexandra Potekhina, Tatiana Arefieva, Anastasiia Filatova, Fail Ageev

Int J Mol Sci· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Blood Immune Cell Alterations in Patients with Hypertensive Left Ventricular Hypertrophy and Heart Failure with Preserved Ejection Fraction.
Artem Ovchinnikov, Anastasiya Filatova, Alexandra Potekhina, Tatiana Arefieva, Anna Gvozdeva, Fail Ageev

J Cardiovasc Dev Dis· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Left atrial dysfunction as the major driver of heart failure with preserved ejection fraction syndrome.
Artem G Ovchinnikov, Alexandra Potekhina, Evgeny Belyavskiy, Anna Gvozdeva, Fail Ageev

J Clin Ultrasound· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Heart Failure with Preserved Ejection Fraction and Pulmonary Hypertension: Focus on Phosphodiesterase Inhibitors.
Artem Ovchinnikov, Alexandra Potekhina, Evgeny Belyavskiy, Fail Ageev

Pharmaceuticals (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Asymptomatic Left Ventricular Hypertrophy Is a Potent Risk Factor for the Development of HFpEF but Not HFrEF: Results of a Retrospective Cohort Study.
Artem Ovchinnikov, Evgeny Belyavskiy, Alexandra Potekhina, Fail Ageev

J Clin Med· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Digital Technology Tools to Characterize Adherence to Prescription-Grade Omega-3 Polyunsaturated Fatty Acid Therapy in Postmyocardial or Hypertriglyceridemic Patients in the DIAPAsOn Study: Prospective Observational Study.
Gregory P Arutyunov, Alexander G Arutyunov, Fail T Ageev, Tatiana V Fofanova

JMIR Cardio· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Digital Technology Tools to Examine Patient Adherence to a Prescription-Only Omega-3 Polyunsaturated Fatty Acid Therapy To Mitigate Cardiovascular Risk: Protocol for a Prospective Observational Study and Preliminary Demographic Analysis.
Gregory P Arutyunov, Alexander G Arutyunov, Fail T Ageev, Tatiana V Fofanova

JMIR Res Protoc· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phosphodiesterase 5 inhibitor sildenafil in patients with heart failure with preserved ejection fraction and combined pre- and postcapillary pulmonary hypertension: a randomized open-label pilot study.
Evgeny Belyavskiy, Artem Ovchinnikov, Alexandra Potekhina, Fail Ageev, Frank Edelmann

BMC Cardiovasc Disord· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of changes in arterial stiffness in men with coronary artery disease.
Iana A Orlova, Eradzh Yu Nuraliev, Elena B Yarovaya, Fail T Ageev

Vasc Health Risk Manag· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Thomas M Suter, Marion Procter, Dirk J van Veldhuisen, Michael Muscholl, Jonas Bergh, Fail T Ageev

J Clin Oncol· September 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis